Literature DB >> 17908944

Antileishmanial structure-activity relationships of synthetic phospholipids: in vitro and in vivo activities of selected derivatives.

Karin Seifert1, Andreas Lemke, Simon L Croft, Oliver Kayser.   

Abstract

Antileishmanial activities of 91 synthetic phospholipids against Leishmania donovani were evaluated in vitro and cytotoxicity assessed against two mammalian cell lines. Promising compounds were tested further in vivo. In vitro structure-activity relationships showed a positive contribution of head groups bearing ring systems (N-methylpiperidino and N-methylmorpholino) to antileishmanial activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908944      PMCID: PMC2167978          DOI: 10.1128/AAC.00465-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

Review 1.  Antiprotozoal activities of phospholipid analogues.

Authors:  Simon L Croft; Karin Seifert; Michael Duchêne
Journal:  Mol Biochem Parasitol       Date:  2003-02       Impact factor: 1.759

2.  Leishmaniasis.

Authors:  Philippe Desjeux
Journal:  Nat Rev Microbiol       Date:  2004-09       Impact factor: 60.633

3.  3D-Quantitative structure-activity relationships of synthetic antileishmanial ring-substituted ether phospholipids.

Authors:  Agnes Kapou; Nikolas P Benetis; Nikos Avlonitis; Theodora Calogeropoulou; Maria Koufaki; Efi Scoulica; Sotiris S Nikolaropoulos; Thomas Mavromoustakos
Journal:  Bioorg Med Chem       Date:  2006-11-14       Impact factor: 3.641

4.  Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

Authors:  Patricia Escobar; Sangeeta Matu; Cláudia Marques; Simon L Croft
Journal:  Acta Trop       Date:  2002-02       Impact factor: 3.112

Review 5.  Hexadecylphosphocholine: a new and selective antitumor drug.

Authors:  H Eibl; C Unger
Journal:  Cancer Treat Rev       Date:  1990-09       Impact factor: 12.111

6.  The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.

Authors:  S L Croft; D Snowdon; V Yardley
Journal:  J Antimicrob Chemother       Date:  1996-12       Impact factor: 5.790

7.  Antileishmanial ring-substituted ether phospholipids.

Authors:  Nikos Avlonitis; Eleni Lekka; Anastasia Detsi; Maria Koufaki; Theodora Calogeropoulou; Efi Scoulica; Eleni Siapi; Ioanna Kyrikou; Thomas Mavromoustakos; Andrew Tsotinis; Simona Golic Grdadolnik; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2003-02-27       Impact factor: 7.446

8.  Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes.

Authors:  V Achterberg; G Gercken
Journal:  Mol Biochem Parasitol       Date:  1987-03       Impact factor: 1.759

Review 9.  Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

Authors:  Philippe J Guerin; Piero Olliaro; Shyam Sundar; Marleen Boelaert; Simon L Croft; Philippe Desjeux; Monique K Wasunna; Anthony D M Bryceson
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071

Review 10.  Analogs of alkyllysophospholipids: chemistry, effects on the molecular level and their consequences for normal and malignant cells.

Authors:  H Brachwitz; C Vollgraf
Journal:  Pharmacol Ther       Date:  1995-04       Impact factor: 12.310

View more
  2 in total

1.  Synthesis and antifungal activities of miltefosine analogs.

Authors:  Ranga Rao Ravu; Ying-Lien Chen; Melissa R Jacob; Xuewen Pan; Ameeta K Agarwal; Shabana I Khan; Joseph Heitman; Alice M Clark; Xing-Cong Li
Journal:  Bioorg Med Chem Lett       Date:  2013-07-06       Impact factor: 2.823

2.  Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridis.

Authors:  T Luke Simmons; Niclas Engene; Luis David Ureña; Luz I Romero; Eduardo Ortega-Barría; Lena Gerwick; William H Gerwick
Journal:  J Nat Prod       Date:  2008-08-21       Impact factor: 4.050

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.